摘要
目的 探讨多发性骨髓瘤(MM)合并骨髓纤维化患者的临床特征及预后.方法 回顾性分析83例MM患者临床资料,将50例单纯MM患者设为对照组,将33例合并骨髓纤维化的MM患者设为观察组.所有患者采用以硼替佐米为基础的化疗方案,并收集疾病分期、分型及遗传学特点相关资料,分析2组疗效及疾病分期、分型、遗传学特点间差异,并随访3年,比较2组预后间差异.结果 观察组有效率低于对照组,差异有统计学意义(P＜0.05).2组DS分期、ISS分期、MM分型相比,差异无统计学意义(P＞0.05);观察组FISH、1q21扩增、D13S319缺失、IGH断裂阳性率高于对照组,差异有统计学意义(P＜0.05).观察组生存率低于对照组,差异有统计学意义(P＜0.05).结论 MM合并骨髓纤维化患者临床疗效偏差,易出现FISH、1q21扩增、D13S319缺失、IGH断裂阳性情况,且整体预后欠佳.
Abstract
Objective To explore the clinical characteristics and prognosis of patients with multiple myeloma(MM)and myelofibrosis.Methods A retrospective analysis was conducted on the clinical data of 83 MM patients,with 50 simple MM pa-tients as the control group and 33 MM patients with bone marrow fibrosis as the observation group.All patients underwent a chem-otherapy regimen based on bortezomib,and relevant data on disease staging,typing,and genetic characteristics were collected.The differences in efficacy,disease staging,typing,and genetic characteristics between the 2 groups were analyzed,and a 3-year follow-up was conducted to compare the differences in prognosis between the 2 groups.Results The effective rate of the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).There was no statistically significant difference between the 2 groups in DS staging,ISS staging,and MM typing(P＞0.05);The positive rates of FISH,1 q21 amplification,D13S319 deletion,and IGH cleavage in the observation group were higher than those in the control group,with statistical significance(P＜0.05).The survival rate of the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).Conclusion The clinical efficacy of patients with MM combined with bone marrow fibrosis is biased,prone to FISH,lq21 amplification,D13S319 deletion,and IGH breakage positivity,and the overall prog-nosis is poor.
维普
万方数据